INVA Innoviva, Inc.
Pharmaceutical Preparations · Nasdaq · SEC CIK 1080014 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY12.8%
TTM net income YoY51.9%
TTM EPS YoY41.6%
Revenue 3-yr CAGR14.7%
Net income 3-yr CAGR57.1%
Margins
Gross margin74.5%
Operating margin38.8%
Net margin44.1%
FCF margin41.6%
EBITDA margin—
Returns
ROE18.0%
ROA13.0%
ROIC (approx.)18.3%
Asset turnover0.30x
Leverage & solvency
Liabilities / assets26.0%
Debt / equity0.23x
Current ratio15.44x
Interest coverage8.64x
Cash quality & payout
Operating cash flow / net income0.95x
Accruals ratio0.7%
Payout ratio—
Capex / revenue0.2%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY2025*2025-12-31 | FY2024*2024-12-31 |
|---|---|---|
| Income statement | ||
| Revenue | $411.33M | $358.71M |
| Gross profit | $307.67M | $296.21M |
| R&D expense | $30.60M | $13.65M |
| SG&A expense | $113.32M | $115.69M |
| Operating income | $163.75M | $166.87M |
| Interest expense | $16.70M | $22.21M |
| Pretax income | $326.86M | $37.39M |
| Income tax | $55.70M | $14.00M |
| Net income | $271.17M | $23.39M |
| EPS (basic) | 4.02 | 0.37 |
| EPS (diluted) | 3.30 | 0.36 |
| Weighted avg. shares (diluted) | 84.76M | 74.19M |
| Balance sheet | ||
| Cash & equivalents | $550.94M | $304.96M |
| Inventory | $39.17M | $33.73M |
| Current assets | $727.51M | $554.31M |
| PP&E, net | $1.55M | $514,000 |
| Goodwill | $17.91M | $17.91M |
| Intangibles | $182.16M | $208.43M |
| Total assets | $1.64B | $1.30B |
| Current liabilities | $49.70M | $236.08M |
| Short-term debt | $0 | $192.03M |
| Long-term debt | $257.73M | $256.32M |
| Total debt | $257.73M | $448.34M |
| Total liabilities | $462.32M | $609.90M |
| Shareholders' equity | $1.17B | $691.16M |
| Net debt | -$293.21M | $143.38M |
| Shares outstanding | 74.64M | 62.66M |
| Cash flow statement | ||
| Operating cash flow | $196.93M | $188.69M |
| Capital expenditure | $1.13M | $270,000 |
| Free cash flow | $195.80M | $188.42M |
| Investing cash flow | $40.50M | -$63.79M |
| Financing cash flow | $8.55M | -$13.45M |
| Stock-based compensation | $9.45M | $6.37M |
| Share buybacks | $4.53M | $14.78M |
Free plan shows the latest 2 periods; Pro shows all 17 🔒
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.